|Full Name||CHK2 checkpoint homolog (S. pombe)|
|Product Description||Rabbit polyclonal antibody to Chk2 (CHK2 checkpoint homolog (S. pombe))|
|Background||In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]|
|Synonyms||CDS1 antibody, CHK2 antibody, HuCds1 antibody, LFS2 antibody, PP1425 antibody, RAD53 antibody, CHEK2 antibody, protein kinase CHK2 antibody, checkpoint-like protein CHK2 antibody, cds1 homolog antibody, serine/threonine-protein kinase Chk2 antibody, CHK2 checkpoint homolog antibody, CHK2 checkpoint homolog (S. pombe) antibody|
|Cellular Localization||Isoform 2: Nucleus , Isoform 4: Nucleus , Isoform 7: Nucleus , Isoform 9: Nucleus , Isoform 12: Nucleus |
|Immunogen||Recombinant protein encompassing a sequence within the C-terminus region of human Chk2. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Predict Reactivity Note||Bovine (87%)|